Search Results

Lysogene Becomes Latest Company to Fail with AAVs in CNS Disorders (Updated)

Lysogene’s investigational gene therapy LYS-SAF302 failed to meet its primary and key secondary efficacy endpoints in mucopolysaccharidosis type IIIA.

November 21, 2022

·

3 min read

·

Tristan Manalac

Lysogene Announces the Extension of Deadline for the Submission of Offers

Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from February 15, 2023 to March 15, 2023 at 12:00.

February 16, 2023

·

3 min read

Lysogene Provides Medical Update

Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, provides a medical update.

February 7, 2022

·

6 min read

Medicine doctor team meeting and analysis. Diagnose checking brain testing result with modern virtual screen interface on laptop with stethoscope in hand, Medical technology network connection concept.

Drug Development

Lysogene Gene Therapy Indicates Potential to Slow Sanfilippo Syndrome

Lysogene’s Phase II/III trial assessing LYS-SAF302 for the treatment of MPS IIIA, also known as Sanfilippo syndrome type A, revealed positive biomarker data, spurring hope for a potential treatment.

July 7, 2022

·

3 min read

·

Heather McKenzie

Business

Lysogene and Sarepta Part Ways on Gene Therapy for Rare Genetic Condition

Lysogene and Sarepta Therapeutics will end a licensing agreement after failed discussions of transferring global commercial supply rights for the LYS-SAF302 asset back to Lysogene.

January 13, 2022

·

2 min read

·

Alvin Clavines

Drug Development

Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study

Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

November 18, 2022

·

12 min read

Drug Development

Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022

Regulatory News: Lysogene announced that it will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA.

November 18, 2022

·

3 min read

Drug Development

Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)

The financing will enable Lysogene to accelerate the development of its gene therapy platform.

December 24, 2021

·

7 min read

Drug Development

Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome

Lysogene announced the publication of a peer-reviewed article in EMBO Molecular Medicine e14649) showing that adeno-associated viral vector-delivered diacylglycerol kinase achieves long-term rescue of fragile X syndrome in a mouse model of disease.

April 21, 2022

·

4 min read

Drug Development

Lysogene Provides Additional Update on AAVance Phase 2/3 Gene Therapy Clinical Trial with LYS-SAF302 in children with MPS IIIA

Regulatory News: Lysogene, a phase 3 gene therapy platform Company targeting central nervous system diseases, communicates additional preliminary data from the AAVance Phase 2/3 gene therapy trial in MPS IIIA.

July 7, 2022

·

8 min read